Skip to main content

Table 2 Sensitivity-analysis of the effect of corticosteroid prophylaxis of post-ERCP pancreatitis in clinical trials

From: Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis

Method

Patients

Pooled OR (95% CI)

p

 

PEP

A

2632

1.13 (0.89, 1.44)

0.32

B

2328

1.20 (0.93, 1.55)

0.17

C

2247

1.10 (0.85, 1.43)

0.47

D

2448

1.13 (0.88, 1.46)

0.34

 

Severe PEP

A

2257

1.61 (0.74, 3.52)

0.23

B

2073

1.80 (0.68, 4.72)

0.23

C

1872

1.35 (0.47, 3.91)

0.58

D

2073

1.80 (0.68, 4.72)

0.23

 

Post-ERCP hyperamylasemia

A

412

0.92 (0.57, 1.48)

0.73

B

228

0.87 (0.52, 1.46)

0.60

C

228

0.87 (0.52, 1.46)

0.60

D

228

0.87 (0.52, 1.46)

0.60

  1. A: all included trials [18–24]
  2. B: we excluded the trials that the allocation concealment was inadequate or unclear [18, 24]
  3. C: we excluded the trials that the blindness was unadopted [18, 21]
  4. D: we excluded the trials which published in the form of abstract [18]